Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
A new coronavirus variant is circulating, the most transmissible one yet. Hospitalizations of infected patients are rising. And older adults represent nearly 90% of U.S. deaths from covid-19 in recent months, the largest portion since the start of the pandemic.
In a recent study posted to the bioRxiv* preprint server, researchers at Emory University used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Washington (WA.1) and Omicron (BA.1) strains to test for mutations that could result in resistance to the antiviral drug nirmatrelvir.
Researchers presented the results of a phase III randomized controlled trial of oral SARS-CoV-2 antiviral VV116.
Researchers assessed the long-term outcomes of critically ill coronavirus disease 2019 (COVID-19) patients.
Researchers investigated the efficacy of ritonavir and nirmatrelvir combination treatment in reducing the risk of COVID-19 severity outcomes such as hospital admissions and deaths when administered during the initial period of SARS-CoV-2 infections.
Researchers assessed the impact of bebtelovimab (BEB) monoclonal antibody in the treatment of high-risk SARS-CoV-2 Omicron variant-infected patients.
Researchers evaluated the effectiveness of SARS-CoV-2 antivirals, nirmatrelvir-ritonavir, and molnupiravir among Veterans in the United States of America.
Researchers evaluated the incidence of COVID-19 rebound among SARS-CoV-2 -positive patients treated with oral antiviral drugs such as nirmatrelvir-ritonavir combination and molnupiravir.
Researchers described the clinical characteristics and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19) in the Netherlands.
Researchers examined the prevalence of contraindications to nirmatrelvir-ritonavir (Paxlovid) in hospitalized coronavirus disease 2019 (COVID-19) patients.
In a recent study published in the journal JAMA Network, researchers in the United States investigated factors that restricted the use of antivirals directed at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States (US) between January and February 2022.
Researchers investigated the short-term outcomes of treating pregnant patients exhibiting mild to moderate symptoms of COVID-19 with Paxlovid, which is a combination of the antivirals nirmatrelvir and ritonavir.
In a recent study posted to the medRxiv* preprint server, researchers in Canada evaluated nirmatrelvir and ritonavir (Paxlovid) effectiveness against severe coronavirus disease 2019 (COVID-19) during the dominance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and Omicron sub-VOCs in Canada.
Influenza infection and hospitalization rates continue to increase at an alarmingly fast and early rate this year.
A new study aimed to analyze the molecular interactions between the hCypA protein and the SARS-CoV-2 variants to determine the impact of variants on the blocking and binding potential of the hCypA–S protein complex with the ACE2 receptor.
Researchers at University of California San Diego School of Medicine, with colleagues from the ACTIV-2 trial, part of the U.S. government's response to COVID-19, investigated whether symptoms of COVID-19 recurred following a two-day symptom-free period in persons who did not receive any treatment for the disease.
Researchers summarized available information related to the reproductive effects of COVID-19 in men.
In a recent study published in the journal eLife, researchers showed the utility of machine-learning models in identifying early immune signatures, which could reliably predict clinical and immunological outcomes in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected outpatients.
Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.
A review of the current approaches to managing COVID-19, including diagnostic, therapeutic, and preventive measures.